Etozolin
Etozolin (W-2900A) is a diuretic agent. Etozolin inhibits fluid and electrolyte reabsorption in the loop of Henle. Etozolin can be used in research of congestive heart failure, hypertension and edema.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 73-09-6
- Fòrmula: C13H20N2O3S
- Peso molecular:284.37
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague dawley rats[1]
-
Dosage:50 mg/kg
-
Administration:Intravenous injection; once
-
Result:Decreased fractional tubular sodium reabsorption by 8.7% and increased urinary fluid and sodium excretion.
Chemical Information
-
No. CAS 73-09-6
-
Peso molecular 284.37
-
Fòrmula C13H20N2O3S
-
SMILES
O=C(OCC)/C=C(N1C)/SC(N2CCCCC2)C1=O
-
Synonyms
W-2900A
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Etozolin Related Classifications
HY-B2081 Related Classifications
Powered by Bioz